Press Releases

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
May 13, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics’ CSO takes temporary leave to undergo medical treatment – Di Yu appointed Acting CSO

Read more
May 11, 2026
2026
Press Release Regulatory

Elicera publishes information document regarding the rights issue

Regulatory
Read more
Apr 21, 2026
2026
Press Release Regulatory

Elicera Therapeutics carries out a rights issue of approximately SEK 73 million

Regulatory
Read more
Apr 21, 2026
2026
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2026

Regulatory
Read more
Mar 20, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics Announces Swedish Cancer Society’s Senior Investigator Award to Chief Development Officer Di Yu

Read more
Mar 11, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate

Read more
Mar 10, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics’ Chief Scientific Officer Magnus Essand named Cancer Researcher of the Year 2026 by the Swedish Cancer Society (Cancerfonden)

Read more
Mar 6, 2026
2026
Press Release Regulatory

Elicera Therapeutics reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients

Regulatory
Read more
Feb 27, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics provides update on preclinical CAR T-cell program ELC-401 for glioblastoma: preclinical development concluded and clinical trial planning underway

Read more
Feb 18, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics to present ipdated CARMA study data on March 6, 2026, at the 10th Zurich Immuno-Oncology Conference

Read more
Feb 13, 2026
2026
Press Release Regulatory

Elicera Therapeutics AB (publ) Year-End 1 January – 31 December 2025

Regulatory
Read more
Feb 11, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics announces abstract acceptance at ISCT 2026 Dublin: Complete metabolic response achieved in four of six patients with iTANK-armed ELC-301 in CARMA Lymphoma Study

Read more
Jan 22, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics’ CSO invited to present at multiple scientific conferences

Read more
Jan 9, 2026
2026
Press Release Non-regulatory

Elicera Therapeutics announces final data from its Phase I/IIa trial demonstrating a favorable safety profile and promising efficacy signals of oncolytic virus ELC-100 in neuroendocrine tumors

Read more
Dec 23, 2025
2025
Press Release Regulatory

Correction: Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ)

Regulatory
Read more
Nov 14, 2025
2025
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim 1 January – 30 September 2025

Regulatory
Read more
Nov 13, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics announces that the Swedish Cancer Society has awarded Professor Magnus Essand at Uppsala University a grant of 7.5 million SEK for CAR T-cell research

Read more
Oct 23, 2025
2025
Press Release Regulatory

Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ)

Regulatory
Read more
Sep 19, 2025
2025
Press Release Non-regulatory

Elicera clarifies status of the iTANK-platform patent application in the U.S.

Read more
Aug 29, 2025
2025
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim 1 January – 30 June 2025

Regulatory
Read more

Sign up for Press Releases

By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.